You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

AZ says MPO inhibitor AZD4831 shows promise in heart failure study

AstraZeneca (AZ) has revealed results from a mid-stage study of its investigational myeloperoxidase (MPO) inhibitor in patients with heart failure with preserved ejection fraction (HFpEF).